

PHARMACEUTICAL INDUSTRY

480.1B

Revenue
(in \$)

20.6B

R&D Spend
(in \$)

7,030

No. of Completed
Project


11,449

No. of Projects


Name

Year


Quarterly Revenue




Quarterly Spend



Drug Approval Status




Project Completion Status




Project Completion Rate

Name	Completion Rate
1. Novartis	94.12
2. Wright, Buchanan and Olsen	93.33
3. Allen, Jones and Krueger	89.29
4. Parker LLC	84.21
5. Williams Group	84
6. Wall Inc	81.82
7. Wright-Vaughan	81.48
8. Juarez Group	81.25
9. Vega, Shelton and Graves	81.25

Completed and Total Projects



Drug Approval/Rejection by company.





Project Approval Success Rate

Name	Drug Approval Success Rate
1. Miller LLC	100
2. Hudson LLC	100
3. Moore-Hernandez	100
4. Harris LLC	92.31
5. Smith, Wright and Hicks	91.67
6. Odom-Johnson	90.91
7. Stein and Sons	90.91
8. Davis, Zimmerman and Nelson	90

R&D spend as percentage of revenue

Name	R&D Spend
1. Salinas, Adams and Dennis	8.7
2. Lawrence, Johnson and Lewis	8
3. Fletcher, Mendoza and Scott	7.8
4. West Ltd	7.7
5. Ellis-Brown	7.6
6. Gomez-Lopez	7.4
7. Hayes Inc	7.4
8. Morales, King and Smith	7.4
9. KCG	7.3
10. Harmon-Johnson	7.2


Average Time to Market for drugs




Return on Investment

Name	Return on Investment
1. Webb, Hall and Valenzuela	38.94
2. Jones LLC	37.76
3. Young and Sons	34.29
4. Ward PLC	33.64
5. Fisher-Lewis	33.31
6. Turner, Contreras and Gutierrez	33.25
7. Brown, Frazier and Alvarez	33.03
8. Thomas-Poole	33.02
9. Jackson, Contreras and Gutierrez	32.99


Top 20 companies by revenue




Top 20 companies by spend



Customer Acquisition Cost




Monthly Customers



Yearly Revenue

Name



Yearly R&D Spend

